Navigation Links
Ingen Technologies, Inc. Press Release Retraction
Date:1/30/2008

YUCAIPA, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (Pink Sheets: IGTG) today is issuing this retraction:

A press release was mistakenly issued on January 23, 2008, announcing an agreement between Ingen Technologies, Inc. and Lincare, Inc. (Nasdaq: LNCR) This is in fact NOT the case at this time. Lincare had simply authorized Ingen as a vendor and authorized Ingen to communicate the Oxyview(R) product to all of their locations through the form of several email communications between Lincare and Ingen. Lincare provided Ingen with the Lincare Locations List in Xcel format. Lincare delivered six purchase orders to purchase a variable amount of Oxyview(R) product from Ingen. There was no written agreement between Lincare and Ingen. There was an understanding between both parties regarding Oxyview(R) pricing and the fact that Lincare authorized Ingen as a vendor to sell Oxyview(R) and communicate directly to more than 1000 Lincare locations. To date, Ingen fulfilled its delivery obligations to Lincare in regards to all of the purchase orders. Ingen understood that Lincare provides services to more than 500,000 patients in the United States. Historically, patients purchasing Oxyview(R) direct from Ingen have purchased two Oxyview's(R), one for their remote oxygen delivery system, either liquid or gas, and one for their in-home concentrator which is a stationary system that produces oxygen from ambient air. This would account for the possibility of 1M Oxyview's(R). Further, there are new oxygen therapy patients entering the market every day, which would account for additional possibilities to place more Oxyview(R) product.

The officials at Ingen Technologies regret any inconvenience due to this erroneous announcement.

Oxyview(R) is a proprietary safety device that received FDA Classification in 2006. This device provides additional confidence to any patient receiving oxygen. It allows the patient to confirm oxygen flow rate and delivery nearest the patient, where it matters the most. Currently there are no other similar devices that offer this technology. Although there are gravity dependent flow meters attached to most oxygen systems that monitor system flow rate, there was nothing available that would attach to the Oxygen tubing to confirm proper oxygen delivery near the patient. Oxyview(R) provides an improved technology to enhance patient confidence and assurance of oxygen flow. Oxyview(R) monitors the oxygen flow the patient is receiving, and does not compete with or replace the current flow meters that are monitoring oxygen flow rate the delivery system is producing. Most Oxygen tubing is 7 feet to 30 feet in length, and the patient is too far away from the delivery source. Oxyview(R) allows convenience for the patient in offering a simple cost effective tool to provide visual flow rate next to the patient.

"When I received email authorization from Lincare early this month, we immediately communicated our Oxyview(R) product to all of their locations in a matter of only a few days. We immediately received purchase orders and hundreds of telephone calls responding positively to our Oxyview(R) product. Unfortunately, we did not request Lincare's authorization of the Press Release of January 23rd, nor were we advised by Lincare of any of their policies prior the Press Release; as such, Lincare abruptly terminated the relationship with Ingen. I have provided several written apologies to the CEO of Lincare and other Lincare management requesting their consideration, with no success. However, we have received a few telephone calls from Lincare location managers requesting information on how their patients can purchase the Oxyview(R) direct from Ingen. I have offered the Lincare patients the same low price that was established with Lincare. Lincare patients can purchase direct from Ingen if they call our office and make a request to purchase Oxyview(R)," stated Scott Sand, Chairman and CEO.

Contact: Scott R. Sand

C.E.O & Chairman

(909) 790-7180


'/>"/>
SOURCE Ingen Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WallSt.net Updates Investment Community Through All-New Interview With Ingen Technologies
2. Ingenious Med Forms Multiple Billing Company Partnerships to Market Inpatient Practice Management Solutions
3. ReBuilder Medical Technologies, Inc. Expands R&D of New Products
4. ReBuilder Medical Technologies, Inc. Announces Televised Broadcast
5. ReBuilder Medical Technologies, Inc. 4th Quarter Sales Increase 100% Exceeding Projections
6. ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October
7. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
8. ReBuilder Medical Technologies, Inc. Announces Record Sales Month
9. ISTO Technologies, Inc. Appoints Blake Miles as Vice President of Sales
10. MagStar Technologies, Inc. Announces Third Quarter 2007 Results
11. ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... RICHEY, Fla. (PRWEB) , ... April 24, 2017 ... ... and Prevention (CDC), rising prescription opioid overdose deaths now claim the lives of ... slashed its civil case filings against drug manufacturers, distributors, pharmacies and prescribers by ...
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively ... it is not known to have significant interactions with antiretroviral therapy (ART). ... cholesterol levels and dampen inflammation in the bloodstream. , While lowering cholesterol and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all sorts of ... of them to be very practical. She wanted to write a guide/workbook that would ... their health. It prompted her in writing “ A Clear Path to a Vibrant ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), ... ANCD BRAIN device as the product advances towards regulatory and clinical phases. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... the "Global Biosimilar Pipeline and Market Prospects: Addressing ... report to their offering. ... "Global Biosimilar Pipeline and Market ... by Design" provides an in-depth assessment of the current ...
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
Breaking Medicine Technology: